Market Newsdesk

HOUSTON, Nov. 06, 2026 (GLOBE NEWSWIRE) — Project Atlas One is moving from plans into equipment. AZIO AI Holdings, Inc. (Nasdaq: AZIO) has containers on the water, equipment coming in one step at a time and a phased build coordinated with Texas site partner Texoil Ventures LLC, alongside its signed 10 MW Power Champion contract.

Contracted today:

Power Champion — 10 MW at $150 per kW per month, or $1.5 million per month at full delivery (about $90 million over 60 months).

What is contracted today
Today, the only signed customer contract at Atlas One is AZIO’s infrastructure hosting agreement with Power Champion: 10 MW at $150 per kW per month, or $1.5 million per month at full delivery and approximately $90 million over the 60-month initial term.

Capacity charges apply only to capacity delivered and energized, and energy is billed separately at $0.13 per kWh. These are contracted capacity economics, not recognized revenue.

No capacity under the Power Champion agreement has been energized to date, and commencement has not been established.

The agreement, announced on Oct. 9, 2026, also carries expansion rights to 50 MW. The 10 MW Power Champion block sits beside — and is separate from — the planned 11 MW Phase One; it is not inside Phase One. That gives AZIO two distinct tracks: executing on its Power Champion agreement and building incremental capacity for other GPU clients.

Containers on the water. Equipment in sequence.
The update marks a shift in where the work is happening. Planning is turning into logistics, with equipment moving through a deliberate sequence of ordering, shipping, receipt and staging, so that each part of the build arrives when the site is ready to use it.

“Containers are on the water, and equipment is coming in one step at a time, exactly the way we planned it,” said Elgin Tracy, Chief Operating Officer of AZIO AI. “We are not trying to land everything at once. Each arrival is matched to the phase it serves, so capital goes to work in order and every step can be measured before we take the next one. That is disciplined execution, and it is how we intend to build Atlas One.”

AZIO AI is building Atlas One as a modular, phased AI compute campus, with capacity planned one megawatt at a time. The Company is breaking the build into practical blocks of work, each with its own equipment, connectivity and site requirements. The near-term focus is to work toward the 6 MW progress target within the planned 11 MW Phase One.

The equipment schedule follows the same logic. Phased arrivals let the team receive, inspect and stage equipment against a defined plan instead of absorbing one large delivery. What the team learns installing one block carries into the next.

Room for other GPU clients
Beside the Power Champion block, AZIO is targeting $255 per kW per month for other GPU clients on incremental capacity. That is a target rate for additional customer business — not a signed contract at $255, and separate from Power Champion’s contracted $150 rate.

At that targeted rate, 6 MW of incremental capacity would represent $1.53 million per month, or approximately $18.4 million per year. The planned 11 MW Phase One would represent $2.805 million per month, or approximately $33.7 million per year. These illustrations sit beside, not inside, the Power Champion economics and depend on additional customer agreements and delivery of the corresponding capacity.

Beyond Phase One, AZIO has described a longer-term planned path of up to 500 MW. That remains a development objective subject to the capital, infrastructure and customer commitments needed for later phases; the focus of this update is the equipment phase now underway.

“The Power Champion contract gives us a defined capacity foundation at $150 per kW per month, and $255 is the rate we are targeting as we bring in other GPU clients,” Tracy said. “Now we are getting equipment in, working toward the 6 MW progress target and building toward the full 11 MW of Phase One. Containers, equipment, capacity — one step at a time, with each step moving Atlas One forward.”

Project Atlas is AZIO AI’s program to develop behind-the-meter, power-backed AI compute campuses in Texas. Atlas One is the first site under the program. The Company is coordinating site readiness with Texoil Ventures LLC so that incoming equipment can be received and staged in step with the phased build.

AZIO’s next steps are concrete: receive and stage incoming equipment, advance installation block by block, work toward the 6 MW progress target and build toward the full 11 MW Phase One alongside the Power Champion contract. The Company expects to provide updates as equipment arrives and phases advance.

For AZIO, each equipment arrival moves the plan forward: receive it, stage it and build the next block.

AZIO AI Holdings, Inc. (Nasdaq: AZIO) develops AI compute and power infrastructure. Project Atlas is its program for behind-the-meter, power-backed AI compute campuses in Texas. More information: www.azioai.ai.

Forward-Looking Statements
This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the Company’s plans to develop Project Atlas One on a modular, phased basis; equipment shipping, delivery, receipt, staging and installation; the planned 11 MW Phase One and 6 MW progress target, incremental to the separate 10 MW Power Champion block; the longer-term development objective of up to 500 MW; performance and economics under the Power Champion agreement; the targeted $255 per kW per month capacity rate for other GPU clients and projected revenue from incremental capacity; and site coordination with Texoil Ventures LLC. Actual results may differ materially because of shipping and supply chain delays, equipment defects or shortfalls, capital availability, fuel or generation constraints, connectivity or interconnection delays, permits and approvals, customer demand and pricing, failure to secure additional customer commitments, counterparty performance or non-payment, capacity delivery or energization delays, changes in law or market conditions, the Company’s limited operating history in AI compute campuses and energy infrastructure, and risks described in its most recent Form 10-K and subsequent Form 10-Q filings at www.sec.gov.

The Power Champion figures of $1.5 million per month and approximately $90 million over 60 months assume the full 10 MW is delivered and energized throughout that term and the counterparty performs. They describe contracted capacity economics, not recognized revenue, and are not assured; they exclude separate energy charges of $0.13 per kWh. The $255 rate is management’s targeted rate for other GPU clients, not a contracted Power Champion rate or a signed contract at $255. Projected incremental capacity figures are illustrations, not guidance, and exclude operating costs, fuel, capital expenditures and other expenses. Their achievement depends on customer agreements, capacity delivery and energization, and may differ materially or not occur. The longer-term capacity objective depends on additional capital, infrastructure and customers and may not be achieved. The Company undertakes no obligation to update these statements except as required by law. This article is not an offer to sell or a solicitation of an offer to buy any security.

Media contact:
Investor Relations
[email protected]

ST. PETERSBURG, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) — The Board of Directors of Superior Group of Companies, Inc. (NASDAQ: SGC) today announced that it has declared a quarterly dividend of $0.14 per share, payable November 25, 2026, to shareholders of record as of November 16, 2026.

About Superior Group of Companies, Inc. (SGC):

Established in 1920, Superior Group of Companies is comprised of three attractive business segments each serving large, fragmented and growing addressable markets. Across Healthcare Apparel, Branded Products and Contact Centers, each segment enables businesses to create extraordinary brand engagement experiences for their customers and employees. SGC’s commitment to service, quality, advanced technology, and omnichannel commerce provides unparalleled competitive advantages. We are committed to enhancing shareholder value by continuing to pursue a combination of organic growth and strategic acquisitions. For more information, visit www.superiorgroupofcompanies.com.

Contact:

Investor Relations
[email protected]

TORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) — Hudbay Minerals Inc. (“Hudbay” or the “Company”) (TSX, NYSE: HBM) today announced that, further to the Company’s news release dated September 28, 2026, the Company has filed a National Instrument 43-101 technical report for its Snow Lake operations in Manitoba (the “2026 Technical Report”).

Hudbay’s 100% owned Snow Lake operations in Manitoba include the Lalor gold-copper-zinc mine, the New Britannia gold mill, the Stall base metals concentrator, the 1901 zinc-gold deposit, several satellite deposits and the former producing New Britannia gold mine currently on care and maintenance.

As disclosed in the September 28, 2026 news release, the highlights of the 2026 Technical Report include:

• An enhanced gold production profile with a 37% increase in gold production over the next five yearsⁱ.
• Total life-of-mine gold production increased by 60% to 2.8 million ounces compared to 1.8 million ounces in the 2021 technical reportⁱ.
• The updated mine plan maintains average annual production of 185,000 ounces of gold over the next five yearsⁱ reflecting several optimization initiatives including higher mill throughput at New Britannia and higher gold recoveries at the Stall mill to better utilize the combined 6,300 tonnes per day of processing capacity. Snow Lake’s proven and probable reserve mine life is extended to 2043.
• Mineral reserve estimates increased to 27 million tonnes containing 2.0 million ounces of gold, representing a 38% increase in tonnage from the January 1, 2026 mineral reserve estimate. The increase in reserves and mine life extension is driven by reserve conversion at Lalor and 1901, higher reserves at the WIM and 3 Zone satellite deposits, and the first reserve estimate for the Talbot and Rail satellite deposits.
• Life-of-mine plan is based on reserve estimates and reflects a conservative view based on Hudbay’s historical high resource-to-reserve conversion rate of 90%ⁱⁱ.

A copy of the 2026 Technical Report will be available on Hudbay’s corporate website at www.hudbay.com, Hudbay’s SEDAR+ profile at www.sedarplus.ca and on Hudbay’s EDGAR profile at www.sec.gov.

Qualified Person and NI 43-101

The 2026 Technical Report is titled “National Instrument 43-101 Technical Report, Lalor and Snow Lake Operations, Manitoba, Canada”, with an effective date of September 1, 2026.

The technical and scientific information in this news release has been approved by Marc-André Brulotte, P. Geo., Executive Director, Global Mineral Resource Evaluation. Mr. Brulotte is a qualified person pursuant to National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”).

The 2026 Technical Report has been prepared pursuant to NI 43-101 under the supervision of Mr. Brulotte. It constitutes the current technical report in respect of Hudbay’s Snow Lake operations and supersedes and replaces all prior technical reports relating to the Snow Lake operations.

Forward-Looking Information

This news release contains forward-looking information within the meaning of applicable Canadian and United States securities legislation. Forward-looking information is not, and cannot be, a guarantee of future results or events. Forward-looking information is based on, among other things, opinions, assumptions, estimates and analyses that, while considered reasonable by the Company at the date the forward-looking information is provided, inherently are subject to significant risks, uncertainties, contingencies and other factors that may cause actual results and events to be materially different from those expressed or implied by the forward-looking information.

Forward-looking information includes, but is not limited to, statements with respect to the Company’s expectations regarding the production, cost profile and development timelines of its Snow Lake operations, including with respect to its anticipated mine life, the potential to extend the mine life, the potential to convert inferred mineral resources into mineral reserves based on historical conversion rates, opportunities to and further optimize the mine plan, and the potential of the former producing New Britannia gold mine currently on care and maintenance, including its potential to become a new anchor deposit, as well as expectations regarding metals prices, operating and capital costs and other assumptions. Forward-looking information is based on, among other things, opinions, assumptions, estimates and analyses that, while considered reasonable by the Company at the date the forward-looking information is provided, inherently are subject to significant risks, uncertainties, contingencies and other factors that may cause actual results and events to be materially different from those expressed or implied by the forward-looking information.

The material factors or assumptions that Hudbay has identified and were applied in drawing conclusions or making forecasts or projections set out in the forward-looking information include, but are not limited to:

• the ability to achieve production, cost and capital expenditure forecasts;
• the ability to obtain the necessary permits and social license to develop the satellite deposits that have been included in the Snow Lake mine plan;
• the ability to execute on the Company’s exploration plans and to advance related drill plans;
• the success of mining, processing, exploration and development activities;
• the scheduled maintenance and availability of the Company’s processing facilities;
• the accuracy of geological, mining and metallurgical estimates;
• anticipated metals prices and the costs of production;
• the supply and demand for metals the Company produces;
• the supply and availability of all forms of energy and fuels at reasonable prices;
• no significant unanticipated operational or technical difficulties;
• the availability of additional financing, if needed;
• the ability to complete project targets on time and on budget and other events that may affect the Company’s ability to develop its projects;
• the timing and receipt of various regulatory and governmental approvals;
• the availability of personnel for the Company’s exploration, development and operational projects and ongoing employee relations;
• maintaining good relations with the employees at the Company’s operations;
• maintaining good relations with the labour unions that represent certain of the Company’s employees in Manitoba;
• maintaining good relations with the communities in which the Company operates, including neighbouring Indigenous communities and local governments;
• no significant unanticipated challenges with stakeholders at the Company’s various projects;
• no significant unanticipated events or changes relating to regulatory, environmental, health and safety matters;
• no contests over title to the Company’s properties, including as a result of rights or claimed rights of Indigenous people;
• no significant unanticipated litigation;
• certain tax matters, including, but not limited to current tax laws and regulations, changes in taxation policies and the refund of certain value added taxes from the Canadian government; and
• no significant and continuing adverse changes in general economic conditions or conditions in the financial markets (including commodity prices and foreign exchange rates).

The risks, uncertainties, contingencies and other factors that may cause actual results to differ materially from those expressed or implied by the forward-looking information may include, but are not limited to, risks generally associated with the mining industry and the current geopolitical environment, including fluctuations in commodity prices, the potential implementation or expansion of tariffs, currency and interest rate fluctuations, energy and consumable prices, supply chain constraints and general cost escalation in the current inflationary environment, uncertainties related to the development and operation of the Company’s projects, risks associated with the development of new projects, risks related to the Snow Lake mine plan, including the ability to sequence the permitting and development of multiple satellite deposits, risks related to historical agreements in respect of the New Britannia mine, risks related to reclamation and closure liabilities, dependence on key personnel and employee and union relations, risks related to political or social instability, unrest or change, risks in respect of Indigenous and community relations, rights and title claims, operational risks and hazards, including the cost of maintaining and upgrading the Company’s tailings management facilities and any unanticipated environmental, industrial and geological events and developments and the inability to insure against all risks, failure of plant, equipment, processes, transportation and other infrastructure to operate as anticipated, compliance with government and environmental regulations, including permitting requirements and anti-bribery legislation, depletion of the Company’s reserves, volatile financial markets and interest rates that may affect the Company’s ability to obtain additional financing on acceptable terms, the failure to obtain or maintain required permits or approvals from government authorities on a timely basis, uncertainties related to the geology, continuity, grade and estimates of mineral reserves and resources and the potential for variations in grade and recovery rates, uncertain costs of reclamation activities, the Company’s liquidity risks and its ability to access capital on acceptable terms, tax refunds, hedging transactions, cybersecurity risks and risks related to the reliability and security of the Company’s information technology and operational technology systems, including risks arising from cyber attacks, ransomware, phishing and other malware, risks associated with the use of artificial intelligence technologies, operational disruptions arising from environmental events such as wildfires or other forms of extreme weather, as well as the other risks discussed under the heading “Risk Factors” in Hudbay’s most recent Annual Information Form for the year ended December 31, 2025 and under the heading “Financial Risk Management” in the Company’s most recent annual management’s discussion and analysis for the year ended December 31, 2025 which are available on the Company’s SEDAR+ profile at www.sedarplus.ca and the Company’s EDGAR profile at www.sec.gov.

Should one or more risk, uncertainty, contingency or other factor materialize or should any factor or assumption prove incorrect, actual results could vary materially from those expressed or implied in the forward-looking information. Accordingly, you should not place undue reliance on forward-looking information. Hudbay does not assume any obligation to update or revise any forward-looking information after the date of this news release or to explain any material difference between subsequent actual events and any forward-looking information, except as required by applicable law.

About Hudbay

Hudbay (TSX, NYSE: HBM) is a copper-focused critical minerals mining company with three long-life operations and a world-class pipeline of copper growth projects in tier-one mining jurisdictions of Canada, Peru and the United States. Hudbay’s operating portfolio includes the Constancia mine in Cusco (Peru), the Snow Lake operations in Manitoba (Canada) and the Copper Mountain mine in British Columbia (Canada). Copper is the primary metal produced by the Company, which is complemented by meaningful gold production and by-product zinc, silver and molybdenum.

Hudbay’s growth pipeline includes the Copper World project in Arizona (United States), the Cactus project in Arizona (United States), the Mason project in Nevada (United States), the Llaguen project in La Libertad (Peru) and several expansion and exploration opportunities near its existing operations.

The value Hudbay creates and the impact it has is embodied in its purpose statement: “We care about our people, our communities and our planet. Hudbay provides the metals the world needs. We work sustainably, transform lives and create better futures for communities.” Hudbay’s mission is to create sustainable value and strong returns by leveraging its core strengths in community relations, focused exploration, mine development and safe, efficient operations.

For further information, please contact:

Candace Brûlé
Senior Vice President, Capital Markets & Corporate Affairs

(416) 362-8181
[email protected]

ⁱ Average gold production over the 2026 to 2030 five-year period. Total life-of-mine (“LOM”) gold production compares total LOM gold production in the 2021 technical report to total LOM gold production in the 2026 updated mine plan plus actual production since 2021.
ⁱⁱ Resource-to-reserve conversion rate based on the historical conversion at the Lalor deposit from 2022 to 2026.

CINCINNATI, Nov. 06, 2026 (GLOBE NEWSWIRE) — Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 70-cents per share on the Company’s capital stock, payable on December 4, 2026, to shareholders of record as of November 16, 2026. This is equal to the dividend paid in September 2026. This represents the 222^nd consecutive quarterly dividend paid by Chemed in its 55 years as a public company.

Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation’s largest provider of end-of-life hospice care and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.

Statements in this press release or in other Chemed communications may relate to future events or Chemed’s future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.

CONTACT:	Michael D. Witzeman
	(513) 762-6714

• Detection of neoantigen-specific T cells directly 
  
  ex vivo
  
  indicates strong EVX-01-induced immune responses
• Data further underlines the strong predictive performance of Evaxion’s AI-Immunology™ platform
• The new biomarker data supplements recently published three-year data showing 89% vaccine target precision and sustained T-cell and clinical responses
  

COPENHAGEN, Denmark, November 6, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 in patients with advanced melanoma (skin cancer).

The data demonstrate potent EVX-01 induced immune responses and further underline the strong predictive performance of Evaxion’s AI-Immunology™ platform. It will be presented in both an oral and a poster session today and tomorrow respectively at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place in Phoenix, Arizona.

“It is exciting to announce yet another set of new and promising data providing insights into the magnitude, quality and systemic impact of EVX-01-induced immunity in advanced melanoma. The data provide a clear demonstration of the very strong immune responses induced by EVX-01 and also validates our AI-Immunology™ platform further. We are looking forward to sharing and discussing this data with both scientific stakeholders and potential business partners at the important SITC meeting”, says Birgitte Rønø, CSO and COO of Evaxion.

Comprehensive data package

The new data adds to EVX-01’s already comprehensive data package which includes three-year clinical response and immune data presented at the European Society for Medical Oncology (ESMO) Congress 2026 held in October. These data showed 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in the phase 2 trial.

New findings include detection of EVX-01 induced neoantigen-specific T-cells directly ex vivo, which is a clear testament to the magnitude of the vaccine-induced immune responses. Ex vivo responses were dominated by CD4+ T-cells, while CD8+ T-cell responses were observed in half of patients.   

The data also documents a significant association (p<0.001) between predictions by AI-Immunology™ and actual T-cell responses, confirming the strong predictive performance of the platform. Essentially, the platform predicts, with very high precision, which neoantigens will illicit the strongest immune responses allowing for selection of these as optimal vaccine targets.

SITC oral and poster presentation details:

• Abstract title: EVX-01 personalized AI-designed vaccine plus pembrolizumab induce neoantigen-specific T-cell responses and systemic immune modulation in advanced melanoma
• Abstract#: 502

Oral presentation:

• Session: 105b: Rapid Oral – Clinical 1
• Location: Phoenix Convention Center, West Building-300 Level – 301BC
• Date/Time: Friday, November 6, 2026, 12:30-1:30pm MT / 20.30-21.30 CET
• Presenter:  Mads Lausen, Senior Scientist at Evaxion

Poster presentation:

• Session: Poster Session
• Location: Phoenix Convention Center, North Building-Lower Level – Exhibition Halls 4-6
• Date/Time: Saturday, November 7, 2026, 12:30-1:30pm & 6:40-8:10pm MT / 20:30-21:30 CET & 02:40-04:10 CET (Sunday, November 8)
• Presenter: Mads Lausen, Senior Scientist at Evaxion

About the phase 2 trial

The phase 2 trial investigated EVX-01 in patients with advanced melanoma (skin cancer). Each patient enrolled in the trial received a unique vaccine designed with Evaxion’s AI-Immunology™ prediction platform and manufactured based on their individual biology.

At two-year follow-up, the trial demonstrated an Objective Response Rate (ORR) of 75% as 12 out of 16 patients had objective clinical responses, with four patients obtaining a complete response. Clinical and T-cell responses were sustained at three-year follow-up. 89% of the EVX-01 neoantigen targets triggered a tumor-specific immune response in the patients.

In the first two-years, patients received EVX-01 in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). In the third year, a subset of patients received EVX-01 as stand-alone therapy. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About EVX-01

EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancer tumors. It is currently being evaluated as a treatment of advanced melanoma and is Evaxion’s lead clinical asset.

Designed with our AI-Immunology™ platform, EVX-01 is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient’s immune system by mounting a targeted response against tumor-specific neoantigens.

Contact information

Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
[email protected]

About Evaxion

Evaxion is a pioneering clinical-stage TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer as well as infectious and autoimmune diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.

We have developed a pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

Lead Plaintiff Deadline: January 4, 2027. Investors who purchased (NASDAQ: LULU) securities between March 18, 2026 and September 3, 2026 may be eligible to recover losses.

NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) — Attorney Advertising–This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lululemon securities between March 18, 2026 and September 3, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/cases/lululemon-athletica-inc-lulu-class-action-lawsuit.

Lululemon Case Details

The Complaint alleges that throughout the Class Period, Defendants failed to disclose that:

1. lululemon’s store traffic and demand for its products was significantly deteriorating as a result of continued negative media and social-media commentary and softer-than-planned new product launches;
2. the foregoing was likely to have a material negative impact on the Company’s business and reputation, rendering its previously issued financial guidance for FY 2026 unrealistic;
3. defendants downplayed the true scope and severity of the foregoing issues;
4. defendants likewise overstated the strength and durability of lululemon’s overall business and turnaround plan, particularly in North America and Mainland China; and
5. as a result, defendants’ public statements were materially false and misleading at all relevant times.

What’s Next for Lululemon Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/cases/lululemon-athletica-inc-lulu-class-action-lawsuit. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Lululemon you have until January 4, 2027, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.

No Cost to Lululemon Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Lululemon Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]

Attorney advertising.
Prior results do not guarantee similar outcomes.

Designated as one of the Top 150 abstracts submitted for the 41

^st

Annual Meeting of the Society for Immunotherapy of Cancer

HCW11-040 is a first-in-class, second-generation, tetravalent pembrolizumab (Keytruda®) based immune checkpoint inhibitor, built with Company’s proprietary non-Fc TRBC platform

HCW11-040 was constructed with interleukin domains (IL-15 and IL-7) paired with a TGF-β trap, that in combination can potentially rejuvenate exhausted T cells for more effective cancer cell killing

HCW11-040 outperformed immune checkpoint inhibitors in converting immunological cold tumors to hot tumors for solid tumor immunotherapy in preclinical studies

MIRAMAR, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company and leading developer in novel multi-functional fusion immunotherapeutics, for the treatment of autoimmune diseases, cancer, and senescence-associated dysplasia, announced the Company’s data update for HCW11-040 was selected as one of the Top 150 Abstracts by the Society for Immunotherapy of Cancer (“SITC”), out of 1,200 abstract submissions, for its scientific rigor, novelty, clarity, and potential impact on cancer immunotherapy. The Company will present the data update at the 41^st Annual Meeting of SITC, taking place from November 4 – 8, 2026, in Phoenix, Arizona.

The Poster (Abstract #394), entitled, “A tetravalent, pembrolizumab-based fusion immunotherapeutic protein targeting exhausted T cells for expansion and activation,” will be presented during the Poster Session at the Poster Hall from 10 a.m.–2 p.m. MT and 6 – 8:10 p.m. MT, on Saturday, November 7.

HCW11-040 is a novel, first-in-class, fusion immunotherapeutic that is designed to block the checkpoint receptors and engage the costimulatory receptors, analogous to taking the foot off the brake and simultaneously hitting the gas. In preclinical studies, the blocking activity of PD1-PDL1 interaction demonstrated by HCW11-040 was comparable to pembrolizumab, a generic form of Keytruda®. HCW11-040 outperformed pembrolizumab in rejuvenating exhausted T cells against human cancer cells. HCW11-050, the mouse homologue of HCW11-040, was also shown to exhibit better anti-solid-tumor activities against cold tumors than immune checkpoint inhibitors in various relevant tumor efficacy preclinical models. It rejuvenated exhausted T cells and promoted T-cell infiltration into tumors to support cold-to-hot tumor conversion. Thus, HCW11-040 represents a novel cancer immunotherapeutic by combining immune checkpoint blockade with potent cytokine-mediated immune activation, enhancing CD8⁺ T-cell migration to tumors, and reducing immunosuppression in the tumor microenvironment.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. and the company is not affiliated with HCWB.

About HCW Biologics:

HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat diseases promoted by chronic inflammation, including autoimmune diseases, cancer, and senescence-associated dysplasia. HCW Biologics is the leader in creation of multi-valent immunotherapeutics with a unique protein-based scaffold, without the antibody Fc domain. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of proinflammatory and senescence-associated diseases and conditions that are promoted by chronic inflammation —and in doing so, improve patients’ quality of life and possibly extend longevity. A key aspect of the Company’s clinical development and financing strategy is to focus on its business development programs, including its commercial-ready reagents to be used in the production of immunotherapeutics for cancer and infectious diseases. To date, the Company has entered into two licensing agreements in which it has licensed exclusive, worldwide rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/

Forward Looking Statements:

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words and include, the actual success and potency of the Company’s second-generation immune checkpoint inhibitor TRBC fusion molecules; the actual success and potency of the Company’s second generation immune checkpoint inhibitor; the ability of HCW11-040 to treat solid tumor cancers; and HCW11-040’s ability to block the checkpoint receptors comparable to pembrolizumab and engage the costimulatory receptors; the ability of HCW11-040 to rejuvenate exhausted T cells and promote T-cell infiltration into tumors. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 31, 2026, and in other filings filed from time to time with the SEC.  

Company Contact:

Dr. Peter Rhode

Chief Scientific Officer and Vice President of Clinical Operations
HCW Biologics Inc.
[email protected]

This press release was published by a CLEAR® Verified individual.

SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of AST SpaceMobile, Inc. (NASDAQ: ASTS) securities between March 4, 2025 and July 15, 2026, both dates inclusive (the “Class Period”), have until Friday, November 13, 2026 to seek appointment as lead plaintiff of the AST SpaceMobile class action lawsuit. Captioned Hunter v. AST SpaceMobile, Inc., No. 26-cv-00378 (W.D. Tex.), the AST SpaceMobile class action lawsuit charges AST SpaceMobile as well as certain of AST SpaceMobile’s executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the

AST SpaceMobile

class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-ast-spacemobile-class-action-lawsuit-asts.html

You can also contact Robbins Geller attorneys

Ken Dolitsky

or

Michael Albert

by calling 800/851-7783 or via e-mail at

[email protected]

.

CASE ALLEGATIONS: AST SpaceMobile, together with its subsidiaries, designs and develops the constellation of BlueBird satellites. According to the complaint, in September 2025, telecommunications company EchoStar Corporation announced that it had entered into a definitive agreement with SpaceX to sell its AWS-4 and H-block spectrum licenses (the “EchoStar Transaction”). The complaint alleges that, in connection with the EchoStar Transaction, SpaceX and EchoStar Corporation agreed to enter into a long-term commercial agreement, enabling EchoStar’s Boost Mobile subscribers to access SpaceX’s next generation direct-to-cellular (“D2C”) service provided by its telecommunications subsidiary Starlink Services, LLC.

The AST SpaceMobile class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) AST SpaceMobile’s increasing capital requirements were likely to increase AST SpaceMobile’s debt load and share dilution with greater frequency and at greater scale than defendants had signaled to investors; (ii) accordingly, defendants had overstated the sufficiency of AST SpaceMobile’s capital and liquidity position to achieve its strategic and business goals; (iii) defendants likewise overstated the durability of AST SpaceMobile’s competitive position in the satellite D2C market; (iv) even following the EchoStar Transaction, defendants continued overstating AST SpaceMobile’s competitive position in the satellite D2C market; (v) AST SpaceMobile was experiencing slow user adoption in the United States and Japan; (vi) the foregoing was likely to have a significant negative impact on AST SpaceMobile’s business and financial prospects; and (vii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired AST SpaceMobile securities during the Class Period to seek appointment as lead plaintiff in the AST SpaceMobile class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the AST SpaceMobile class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the AST SpaceMobile class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the AST SpaceMobile class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
            Robbins Geller Rudman & Dowd LLP
            Ken Dolitsky
            Michael Albert
            655 W. Broadway, Suite 1900, San Diego, CA 92101
            800/851-7783
            [email protected]

FREDERICK, Md., Nov. 06, 2026 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today announced it will reschedule its conference call to report financial results for the third quarter ended September 30, 2026, to Thursday, November 12, 2026 at 4:30 p.m. ET, and will report results after the close of the financial markets that day. The call was originally scheduled to be held today, Friday, November 6, 2026.

The Company and its independent auditor require additional time to finalize the review of the Company’s financial statements.

To participate in the call by phone, dial (888) 506-0062 approximately five minutes prior to the scheduled start time and provide participant access code 271346, or request the “TOMI Environmental Solutions third quarter earnings call.” International callers please dial (973) 528-0011. To access the live webcast or view the press release, please visit the Investor Relations section of the TOMI website or register at the following link:

https://www.webcaster5.com/Webcast/Page/2262/54772

A replay of the teleconference will be available until November 19, 2026, and may be accessed by dialing (877) 481-4010. International callers may dial (919) 882-2331. Callers should use replay access code: 54772. A replay of the webcast will be available for at least 90 days on the company’s website, starting approximately one hour after the completion of the call.

About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®

TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.

TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.

TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.

For additional information, please visit https://www.steramist.com or contact us at [email protected].

Forward-Looking Statements

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.

INVESTOR RELATIONS CONTACT: 
John Nesbett/Zach Nevas
IMS Investor Relations 
[email protected]